All In MedTech

Device Trial Radar · NCT05597891

Endovascular Engineering ENGULF Study

A Safety and Feasibility Single-Arm Study of a Novel Catheter Thrombectomy Device For the Treatment of Pulmonary Embolism (ENGULF)

Last checked: Nov 20, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

177

Actual

Start

Jan 12, 2023

Primary completion

Mar 2, 2026

Study completion Mar 30, 2026

Sponsor

Lead sponsor
Endovascular EngineeringNot on our public-company list
Sponsor type
Industry
First posted
Oct 28, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluation of initial safety and clinical feasibility of the Hēlo PE Thrombectomy System for thrombectomy in acute submassive pulmonary embolism (PE).

Conditions

  • Pulmonary Embolism

Interventions

  • Hēlo PE Thombectomy SystemDevice

    Treatment with the Hēlo PE Thombectomy System for thromboembolectomy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety ObjectiveTime frame: 48 hours following the procedure
  2. Primary Performance ObjectiveTime frame: 48 hours following the procedure

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • PIH Health Good Samaritan Hospital

    Los Angeles, California

  • Huntington Hospital

    Pasadena, California

  • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

18 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.